- Home
- PSNL
PSNL
Personalis Inc.
as of 12-11-2025 3:43pm EST
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 872.1M | IPO Year: | 2019 |
| Target Price: | $10.71 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.83 - $11.40 | Next Earning Date: | 11-04-2025 |
| Revenue: | $69,103,000 | Revenue Growth: | -21.02% |
| Revenue Growth (this year): | -15.74% | Revenue Growth (next year): | 20.33% |
AI-Powered PSNL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Personalis Inc. (PSNL)
PRESIDENT AND CEO
Avg Cost/Share
$8.99
Shares
29,612
Total Value
$266,211.88
Owned After
148,486
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hall Christopher M | PSNL | PRESIDENT AND CEO | Nov 3, 2025 | Sell | $8.99 | 29,612 | $266,211.88 | 148,486 |
Compare PSNL vs Leading Stocks
See how PSNL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PSNL Personalis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.